CR11136A - INHIBICION DE ARNi DE EXPRESION DE ALFA-ENaC - Google Patents

INHIBICION DE ARNi DE EXPRESION DE ALFA-ENaC

Info

Publication number
CR11136A
CR11136A CR11136A CR11136A CR11136A CR 11136 A CR11136 A CR 11136A CR 11136 A CR11136 A CR 11136A CR 11136 A CR11136 A CR 11136A CR 11136 A CR11136 A CR 11136A
Authority
CR
Costa Rica
Prior art keywords
arni
alfa
inhibition
enac expression
enac
Prior art date
Application number
CR11136A
Other languages
English (en)
Inventor
Van Heeke Gino
Hickman Emma
Luke Danahay Henry
Tan Pamela
Geick Anke
Vornlocher Hans-Peter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR11136A publication Critical patent/CR11136A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl

Abstract

La invencion se refiere a composiciones y metodos para modular la expresion de alfa-ENaC, mediante oligonucleotidos quimicamente modificados.
CR11136A 2007-06-15 2009-12-02 INHIBICION DE ARNi DE EXPRESION DE ALFA-ENaC CR11136A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07110376 2007-06-15
EP07114265 2007-08-13

Publications (1)

Publication Number Publication Date
CR11136A true CR11136A (es) 2010-01-20

Family

ID=40130244

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11136A CR11136A (es) 2007-06-15 2009-12-02 INHIBICION DE ARNi DE EXPRESION DE ALFA-ENaC

Country Status (26)

Country Link
US (12) US7718632B2 (es)
EP (7) EP2223694B1 (es)
JP (6) JP5485146B2 (es)
KR (2) KR101821081B1 (es)
CN (1) CN101778941B (es)
AR (1) AR066984A1 (es)
AU (1) AU2008263876B2 (es)
BR (1) BRPI0813680A8 (es)
CA (1) CA2690674C (es)
CL (1) CL2008001756A1 (es)
CO (1) CO6251331A2 (es)
CR (1) CR11136A (es)
CU (1) CU23774A3 (es)
EA (1) EA200901653A1 (es)
EC (1) ECSP099794A (es)
ES (6) ES2432157T3 (es)
GT (1) GT200900315A (es)
IL (1) IL202366A0 (es)
MA (1) MA31564B1 (es)
MX (1) MX2009013609A (es)
PE (1) PE20090942A1 (es)
SG (3) SG10201404955RA (es)
SV (1) SV2009003434A (es)
TN (1) TN2009000521A1 (es)
TW (3) TWI629063B (es)
WO (1) WO2008152131A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4709545B2 (ja) * 2002-07-26 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 修飾された低分子干渉ｒｎａ分子および使用方法
KR100473148B1 (ko) * 2002-11-27 2005-03-10 (주)텔리언 버스트모드 패킷 전달을 위한 정합장치 및 방법
WO2006039656A2 (en) * 2004-10-01 2006-04-13 Novartis Vaccines And Diagnostics Inc. Modified small interfering rna molecules and methods of use
US8765704B1 (en) 2008-02-28 2014-07-01 Novartis Ag Modified small interfering RNA molecules and methods of use
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
US20110288154A1 (en) * 2008-11-26 2011-11-24 Merck & Co., Inc. RNA Interference Mediated Inhibition of Epithelial Sodium Channel (ENaC) Gene Expression Using Short Interfering Nucleic Acid (siNA)
CN103275978B (zh) * 2009-04-03 2014-10-29 百奥迈科生物技术有限公司 修饰的小干扰核酸及其制备方法
WO2010111891A1 (zh) * 2009-04-03 2010-10-07 北京大学 修饰的寡聚核酸分子及其制备方法和应用
EP2756845B1 (en) * 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
US20120207818A1 (en) * 2009-07-14 2012-08-16 Shinohara Fumikazu Composition for suppressing expression of target gene
WO2011046983A2 (en) * 2009-10-12 2011-04-21 Smith Holdings, Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
WO2011073326A2 (en) 2009-12-18 2011-06-23 Novartis Ag Organic compositions to treat hsf1-related diseases
WO2011131707A1 (en) 2010-04-23 2011-10-27 Novartis Ag ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
EP2694670B1 (en) 2011-04-08 2017-07-19 Bio-Rad Laboratories, Inc. Pcr reaction mixtures with decreased non-specific activity
JP2014519806A (ja) 2011-04-20 2014-08-21 スミス ホールディングス，エルエルシー 細胞内で自己会合し、ＲＮＡｉ活性を産生する組成物を使用した遺伝子発現を調節するための方法および成分
CA3185394A1 (en) 2011-09-02 2013-03-07 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat hsf1-related diseases
KR102634762B1 (ko) 2016-11-01 2024-02-06 애로우헤드 파마슈티컬스 인코포레이티드 알파-v 베타-6 인테그린 리간드 및 그의 용도
CA3061752A1 (en) * 2017-07-06 2019-01-10 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of alpha-enac and methods of use
PE20200749A1 (es) * 2017-10-31 2020-07-24 Ionis Pharmaceuticals Inc Moduladores de la expresion de enac
TN2020000059A1 (en) 2017-11-01 2022-01-06 Arrowhead Pharmaceuticals Inc Integrin ligands and uses thereof
CN109364248B (zh) * 2018-10-16 2021-05-18 哈尔滨医科大学 ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用
US20220339136A1 (en) * 2019-08-30 2022-10-27 United States Government As Represented By The Department Of Veterans Affairs Liposomal troponoid compound formulations
US11957178B2 (en) 2021-11-15 2024-04-16 Apackaging Group Llc Aerosol actuator

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4837026A (en) * 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
DE3604625C2 (de) * 1986-02-14 1994-01-20 Bmw Rolls Royce Gmbh Gasturbine
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5451670A (en) * 1987-12-09 1995-09-19 City Of Hope Restriction fragment length polymorphism test for haplotyping domesticated fowl
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5013566A (en) * 1988-12-19 1991-05-07 Sampson Michael James Process for obtaining improved yields from plants used for hay making by using a coating agent
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
WO1994018987A1 (en) 1993-02-19 1994-09-01 Nippon Shinyaku Co., Ltd. Drug composition containing nucleic acid copolymer
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5540935A (en) 1993-12-06 1996-07-30 Nof Corporation Reactive vesicle and functional substance-fixed vesicle
JP3543347B2 (ja) * 1994-01-24 2004-07-14 日本油脂株式会社 点火薬造粒物の製造方法
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
DE69629702T2 (de) 1995-08-01 2004-06-17 Isis Pharmaceuticals, Inc., Carlsbad Liposomale oligonukleotidzusammensetzungen
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US5865710A (en) * 1996-08-01 1999-02-02 Wilson-Hyde; Cynthia Step aerobic platform
EP0975798A1 (en) * 1997-03-11 2000-02-02 Yale University Method to diagnose and treat pathological conditions resulting from deficient ion transport such as pseudohypoaldosteronism type-1
US6887906B1 (en) 1997-07-01 2005-05-03 Isispharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US5976849A (en) 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
US8137695B2 (en) 2006-08-18 2012-03-20 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
JP4095895B2 (ja) * 2000-12-01 2008-06-04 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー．ヴェー． Ｒｎａ干渉を媒介する短鎖ｒｎａ分子
CN1526025A (zh) 2001-05-16 2004-09-01 ��˹��ŵ�� 作为预后和治疗靶标的乳腺癌中表达的基因
WO2003057847A2 (en) 2001-12-31 2003-07-17 Algos Therapeutics , Inc. METHODS AND MATERIALS FOR MODULATING ENaC-BETA
JP4709545B2 (ja) 2002-07-26 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 修飾された低分子干渉ｒｎａ分子および使用方法
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
GB0218970D0 (en) 2002-08-14 2002-09-25 Creative Peptides Sweden Ab Fragments of Insulin c-peptide
EP2314691A3 (en) * 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
EP1573045A4 (en) 2002-11-27 2007-02-21 Artesian Therapeutics Inc DETECTION OF GENES RELATED TO HEART FAILURE AND THERAPEUTIC ASSAY
BRPI0215958B1 (pt) 2002-11-29 2016-11-08 Basf Ag métodos para produção de metionina
DE10305213A1 (de) 2003-02-07 2004-08-26 Florian Prof. Dr.med. Lang Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms
AU2004227915A1 (en) * 2003-03-31 2004-10-21 John F. Engelhardt Pharmico-gene theraphy of epithelial sodium channel associated disoders
US7723509B2 (en) * 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
WO2004094636A1 (en) 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs
US20050256071A1 (en) * 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
JP4530335B2 (ja) * 2004-02-03 2010-08-25 独立行政法人科学技術振興機構 膀胱に発現する上皮型ナトリウムチャネルに対する阻害薬
EP1752536A4 (en) * 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
SE0402832D0 (sv) * 2004-11-18 2004-11-18 Astrazeneca Ab Methods
US7923206B2 (en) * 2004-11-22 2011-04-12 Dharmacon, Inc. Method of determining a cellular response to a biological agent
AU2005316384B2 (en) * 2004-12-14 2012-02-09 Alnylam Pharmaceuticals, Inc. RNAi modulation of MLL-AF4 and uses thereof
US8101741B2 (en) * 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
WO2007070509A2 (en) * 2005-12-13 2007-06-21 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Epithelial sodium channel inhibiting agents and uses therefor
SG166778A1 (en) 2006-10-11 2010-12-29 Max Planck Gesellschaft Influenza targets
AR066984A1 (es) * 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)

Also Published As

Publication number Publication date
TWI444474B (zh) 2014-07-11
KR101653008B1 (ko) 2016-08-31
EP2223693A1 (en) 2010-09-01
TW200911989A (en) 2009-03-16
EP2224005B1 (en) 2013-09-11
SV2009003434A (es) 2011-03-23
US9074212B2 (en) 2015-07-07
EP2223695B1 (en) 2013-07-24
JP7157775B2 (ja) 2022-10-20
US20100210513A1 (en) 2010-08-19
US20100216972A1 (en) 2010-08-26
US10544418B2 (en) 2020-01-28
CA2690674C (en) 2018-09-11
US20150284726A1 (en) 2015-10-08
US8119612B2 (en) 2012-02-21
AU2008263876B2 (en) 2012-04-12
JP2015145393A (ja) 2015-08-13
TN2009000521A1 (en) 2011-03-31
ES2439277T3 (es) 2014-01-22
KR20100039335A (ko) 2010-04-15
EA200901653A1 (ru) 2010-06-30
US20180148726A1 (en) 2018-05-31
JP5485146B2 (ja) 2014-05-07
SG169988A1 (en) 2011-04-29
CO6251331A2 (es) 2011-02-21
SG10201404955RA (en) 2014-10-30
US20220235361A1 (en) 2022-07-28
EP2223692A1 (en) 2010-09-01
EP2171059A2 (en) 2010-04-07
TWI629063B (zh) 2018-07-11
BRPI0813680A8 (pt) 2018-08-28
EP2223694B1 (en) 2013-07-24
ES2432158T3 (es) 2013-12-02
US8168606B2 (en) 2012-05-01
US20200157550A1 (en) 2020-05-21
EP2224005A1 (en) 2010-09-01
US9476052B2 (en) 2016-10-25
MA31564B1 (fr) 2010-08-02
CN101778941A (zh) 2010-07-14
CN101778941B (zh) 2013-05-22
EP2223693B1 (en) 2013-07-24
GT200900315A (es) 2011-10-05
US20160376599A1 (en) 2016-12-29
TW201524510A (zh) 2015-07-01
US7939508B2 (en) 2011-05-10
US20100210514A1 (en) 2010-08-19
US20100190714A1 (en) 2010-07-29
JP2017222704A (ja) 2017-12-21
SG10201601846VA (en) 2016-04-28
ES2432643T3 (es) 2013-12-04
US7718632B2 (en) 2010-05-18
AR066984A1 (es) 2009-09-23
JP5719047B2 (ja) 2015-05-13
US20220112505A1 (en) 2022-04-14
US20100216971A1 (en) 2010-08-26
US7943592B2 (en) 2011-05-17
ECSP099794A (es) 2010-01-29
EP2223695A1 (en) 2010-09-01
US9914927B2 (en) 2018-03-13
JP2014129373A (ja) 2014-07-10
TW201636027A (zh) 2016-10-16
ES2432532T3 (es) 2013-12-04
BRPI0813680A2 (pt) 2015-01-06
US11208662B2 (en) 2021-12-28
ES2432644T3 (es) 2013-12-04
MX2009013609A (es) 2010-01-20
JP2010530369A (ja) 2010-09-09
JP6193906B2 (ja) 2017-09-06
WO2008152131A3 (en) 2009-05-28
US20090156529A1 (en) 2009-06-18
JP2022188234A (ja) 2022-12-20
BRPI0813680B1 (pt) 2018-02-06
EP2223692B1 (en) 2013-07-24
IL202366A0 (en) 2011-08-01
CA2690674A1 (en) 2008-12-18
KR101821081B1 (ko) 2018-01-23
EP2224004A1 (en) 2010-09-01
EP2223694A1 (en) 2010-09-01
CL2008001756A1 (es) 2009-02-20
ES2432157T3 (es) 2013-12-02
AU2008263876A1 (en) 2008-12-18
TWI552753B (zh) 2016-10-11
JP2020094063A (ja) 2020-06-18
KR20160105530A (ko) 2016-09-06
JP6680728B2 (ja) 2020-04-15
EP2224004B1 (en) 2013-07-24
PE20090942A1 (es) 2009-08-05
CU23774A3 (es) 2012-02-15
WO2008152131A2 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
CR11136A (es) INHIBICION DE ARNi DE EXPRESION DE ALFA-ENaC
DOP2012000038A (es) Conjugados de dímeros de pirrolo [1,4] benzodiazepina como agentes anticancerosos
PA8774501A1 (es) Nueva sales y sus usos
HN2008001191A (es) Compuestos de biciclolactama sustituida
UA107791C2 (en) Pesticidal compositions
EA200801959A1 (ru) Высокоразветвленный полипропилен
EA200801758A1 (ru) Лекарственные формы, устойчивые к самовольному изменению
CR10328A (es) Compuestos organicos
HN2011001247A (es) Inhibidores de cinana akt y p70 s6
CL2008002775A1 (es) Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
UY30225A1 (es) Composiciones farmacéuticas
RS54217B1 (en) SOME TRIAZOLOPIRAZINS, THEIR COMPOSITIONS AND THE METHODS OF USING THEM
CO6220968A2 (es) Inhibidores heterociclicos de la aspartil proteasa
UY32469A (es) Composiciones y metodos para modular la senda de señalizacion de wnt
EA201001710A2 (ru) Фармацевтическая композиция, которая содержит соль стронция, витамин d и циклодекстрин
CR11266A (es) Derivados de pirrolidin-2ona como moduladores del receptor de androgeno
HN2008001723A (es) Nitrilos espirociclicos como inhibidores de proteasa
UY31688A1 (es) Plaguicidas
CL2008000585A1 (es) Compuestos derivados de nicotinamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada por prostaglandina d2 producida por h-pgds.
PA8657801A1 (es) Aminalcoholes triciclicos, procedimientos para su preparacion
CR11423A (es) NUEVOS INHIBIDORES DE sEH Y SU USO
CR10557A (es) Bencilaminas, un proceso para la produccion y su uso como agentes antiinflamatorios
RS54158B1 (en) AMILOID BINDING AGENTS
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
UY31128A1 (es) Formulacion de nevirapina de liberacion prolongada

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)